Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 5:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 90 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Kerato Conjunctivitis Sicca Clear all

Conditions: Systemic Lupus Erythematosus, Sjögren's Disease, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies, Systemic Sclerosis, Lupus Nephritis
Interventions: BMS-986553; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 11
States / cities: Newport Beach, California • Worcester, Massachusetts • Ann Arbor, Michigan + 7 more

Conditions: Keratoconjunctivitis Sicca
Interventions: Rebamipide 1%, Rebamipide 2%, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 762 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 60
States / cities: Birmingham, Alabama • Flagstaff, Arizona • Little Rock, Arkansas + 47 more

Conditions: Sjogren's Syndrome, Keratoconjunctivitis Sicca
Interventions: Levocarnitine, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Dry Eye, Dry Eye Syndromes, Dry Eyes Chronic
Interventions: Lifitegrast 5% Ophthalmic Solution; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Keratoconjunctivitis Sicca
Interventions: glycerin, polyethylene glycol 400/propylene glycol; Drug
Lead sponsor: Calm Water Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Dry Eye
Interventions: ECF843, ECF843 vehicle; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 718 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 52
States / cities: Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 46 more

Conditions: Dry Eye Syndromes, Dry Eye Disease, Kerato Conjunctivitis Sicca
Interventions: 5% Tavilermide ophthalmic solution, Vehicle ophthalmic solution; Drug · Other
Lead sponsor: Mimetogen Pharmaceuticals USA, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 642 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 29
States / cities: Phoenix, Arizona • Glendale, California • Murrieta, California + 25 more

Conditions: Dry Eye Syndromes
Interventions: Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate; Drug
Lead sponsor: Sight Medical Doctors PLLC; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Brentwood, New York

Conditions: Sjogren Disease
Interventions: Sibeprenlimab, Placebo; Biological · Other
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 20
States / cities: Riverside, California • Tujunga, California • Brandon, Florida + 15 more

Conditions: Keratoconus, Ocular Surface Disease, Pellucid Marginal Corneal Degeneration, Ectasia, Corneal Trauma, Corneal Scar, Dry Eye Syndromes, Keratoconjunctivitis Sicca, Sjogren's Syndrome
Interventions: Ocular surface optical coherence tomography; Device
Lead sponsor: Boston Sight; Other
Eligibility: 21 Years and older
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Needham, Massachusetts

Conditions: Dry Eye Syndrome, Keratoconjunctivitis Sicca
Interventions: Oculeve Intranasal, Sham, Oculeve Extranasal; Device
Lead sponsor: Oculeve, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 2
States / cities: Waterbury, Connecticut • Norfolk, Virginia

Conditions: Dry Eye Syndrome, Keratoconjunctivitis Sicca
Interventions: 0.05% Voclosporin Ophthalmic Solution (VOS), 0.10% VOS, 0.20% VOS, Vehicle Ophthalmic Solution; Drug
Lead sponsor: Aurinia Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 508 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 9
States / cities: Newport Beach, California • Colorado Springs, Colorado • Louisville, Kentucky + 6 more

Conditions: Keratoconjunctivitis Sicca
Interventions: voclosporin ophthalmic solution; Drug
Lead sponsor: Lux Biosciences, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Conshohocken, Pennsylvania

Conditions: Keratoconjunctivitis Sicca
Interventions: PRK with conjunctival impression cytology before and after surgery, LASIK with conjunctival impression cytology before and after surgery; Procedure
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 21 Years to 40 Years
Enrollment: 146 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Sjögren's Syndrome
Interventions: Not listed
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Dry Eye Syndromes, Keratoconjunctivitis Sicca
Interventions: KPI-121 0.25% Ophthalmic Suspension, Vehicle of KPI-121 0.25% Ophthalmic Suspension; Drug
Lead sponsor: Kala Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 918 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 60
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 53 more

Conditions: Dry Eye Syndromes
Interventions: Dextenza 0.4Mg Intracanalicular Insert, Over the counter Artificial tears; Drug · Other
Lead sponsor: The Eye Centers of Racine and Kenosha; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Racine, Wisconsin

Conditions: Dry Eye Syndrome
Interventions: PG101; Drug
Lead sponsor: Rhodes Pharmaceuticals, L.P.; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Keratoconjunctivitis Sicca
Interventions: Not listed
Lead sponsor: TearLab Corporation; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 314 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 6
States / cities: San Diego, California • Louisville, Kentucky • Chesterfield, Missouri + 3 more

Conditions: Dry Eyes
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Dry Eye Disease
Interventions: 0.003% AR-15512 ophthalmic solution, Artificial Tears; Drug · Other
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Louisville, Kentucky • Garner, North Carolina • Leland, North Carolina + 1 more

Conditions: Keratoconjunctivitis Sicca, Dry Eye Syndromes, Ocular Surface Disease, Sjogren's Syndrome
Interventions: Questionnaires, Tear fluid sampling, Impression Cytology; Diagnostic Test
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Dry Eye
Interventions: RPS InflammaDry Detector™; Device
Lead sponsor: Rapid Pathogen Screening; Industry
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 8
States / cities: Bradenton, Florida • Miami, Florida • Springfield, Missouri + 4 more

Conditions: Ectropion
Interventions: Hyaluronic acid, Saline; Procedure
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 21 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases

Study of Rebamipide Eye Drops to Treat Dry Eye

Levocarnitine for Dry Eye in Sjogren's Syndrome

Effect of Lifitegrast 5% on Tear Film Markers

Tear Film Break-up Time After Instillation of Artificial Tears

A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease

Efficacy and Safety Evaluation of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye

Evaluation Of Vision Recovery And Comfort Index In Patients With Borderline/Mild Dry Eyes Undergoing FLACS With Premium IOL

A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's

Pilot Study to Investigate the Feasibility, Reliability and Efficacy of Utilizing OCT to Automate PROSE Fitting

A Study to Evaluate the Safety and Effectiveness of Oculeve Intranasal Lacrimal Neurostimulator in Participants With Dry Eye Syndrome

Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome

A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS)

Goblet Cell Response and Dry Eye Symptoms After PRK and LASIK

Salivary Biomarkers for Sjögren's Syndrome Detection

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease

ACCURATE Study for Subjects With Dry Eyes

Safety and Efficacy of PG101 for Dry Eye Syndrome

TearLab Core Validation Study to Establish Referent Values for Dry Eye Disease

Ocular Surface Dry Eye Microbiome

A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease

Differential Diagnosis of Sjögren's Versus Non-Sjögren's Dry Eye

RPS InflammaDry Detector™ to Determine MMP-9 Levels in Tears

Hyaluronic Acid Gels for Lower Lid Retraction